RxDoctor Payments Data

Emmanuel Opara, MD

Internal Medicine · Sugar Land, TXNPI 1538303623

Payments from drug & device makers

$10,211in general payments, 2019–2025

Across 263 payments — averaging $38.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$718
  • Paratek Pharmaceuticals, Inc.$613
  • Sunovion Pharmaceuticals Inc.$509
  • Merck$444
  • AbbVie$271
  • plus $2K from 38 others

What the payments were for

  • Consulting fees$5,36553%
  • Food & beverage$4,84647%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,211 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$343,513
Medicare patients
512
Services billed
3,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$21,973
EliquisApixaban15$9,337
XareltoRivaroxaban15$9,192
JanuviaSitagliptin Phosphate11$5,479
BrilintaTicagrelor13$5,376
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen124$1,619
Nifedipine ErNifedipine21$899
Atorvastatin Calcium120$620
Gabapentin100$596
Albuterol Sulfate HfaAlbuterol Sulfate19$548
Tizanidine Hcl59$441
Metoprolol Tartrate48$413
Potassium Chloride44$396
Levetiracetam21$396
Olanzapine13$381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$52$21,97320 claims
PfizerEliquis$230$9,33715 claims
Johnson & JohnsonXarelto$114$9,19215 claims
MerckJanuvia$444$5,47911 claims
AstraZenecaBrilinta$5,389$5,37613 claims
Lilly USA, LLCOlanzapine$46$38113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →